Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Reiter

Showing results (351-360 of 386) with videos related to

Pageof 39
Sort By:
European Urology|March 15, 2024
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate CancerNicholas G Nickols, Sonny Tsai, Nathanael Kane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U Kishan, Luca F Valle, Holly Wilhalme, et al.
European Urology|September 18, 2024
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate CancerAdam B Weiner, Raag Agrawal, Nicholas K Wang, et al.
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
European Urology|May 29, 2020
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate CancerAmar U Kishan, Tahmineh Romero, Mohammed Alshalalfa, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Pageof 39

Showing results (351-360 of 386) with videos related to

Sort By:
Pageof 39
European Urology|March 15, 2024
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate CancerNicholas G Nickols, Sonny Tsai, Nathanael Kane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U Kishan, Luca F Valle, Holly Wilhalme, et al.
European Urology|September 18, 2024
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate CancerAdam B Weiner, Raag Agrawal, Nicholas K Wang, et al.
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
European Urology|May 29, 2020
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate CancerAmar U Kishan, Tahmineh Romero, Mohammed Alshalalfa, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Pageof 39